Cargando…
B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells
Cancer stem cells (CSCs) have been implicated in metastasis, relapse, and therapeutic resistance of cancer, so successful cancer therapy may therefore require the development of drugs against CSCs or combining anti-CSCs drugs with conventional therapies. The phosphoinositide 3-kinase (PI3K) signalin...
Autores principales: | Zhou, Hongyu, Yu, Chunlei, Kong, Lingmei, Xu, Xiaoliang, Yan, Juming, Li, Yingchao, An, Tao, Gong, Liang, Gong, Yaxiao, Zhu, Huifang, Zhang, Hongbin, Yang, Xiaodong, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756013/ https://www.ncbi.nlm.nih.gov/pubmed/30635656 http://dx.doi.org/10.1038/s41388-018-0674-5 |
Ejemplares similares
-
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
por: Rewcastle, Gordon W, et al.
Publicado: (2017) -
Star-PAP regulates tumor protein D52 through modulating miR-449a/34a in breast cancer
por: Duan, Aizhu, et al.
Publicado: (2019) -
Trichothecin Induces Cell Death in NF-κB Constitutively Activated Human Cancer Cells via Inhibition of IKKβ Phosphorylation
por: Su, Jia, et al.
Publicado: (2013) -
Buparlisib is a brain penetrable pan-PI3K inhibitor
por: de Gooijer, Mark C., et al.
Publicado: (2018) -
SUN-591 Severe Iron-Deficiency Anemia Leading to Hypothyroidism
por: Ghiya, Ronak, et al.
Publicado: (2019)